Stock(600222)Hot line:010-61006450
About

About Us

Stock(600222)

Leadingpharm (stock code: 600222) was established in 2005 with a registered capital of 91.554 million yuan. It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services worldwide. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises " for many years (ranked first in 2019). The company is headquartered in Beijing Zhongguancun High-tech Park and has established new drug screening and testing platform, drug evaluation platform (animal room, certified by GLP, AAALAC, CNAS), large molecule pilot and large-scale production platform, small molecule CMC research and production platform, cell technology platform and clinical CRO platform in Zhengzhou Linkong Biological Park. The six platforms comply with international standards (FDA, EMA and NMPAGMP) , forming " Leadingpharm CXO" whole industry chain service system. The combination of imitation and creation, driven by dual engines, can provide customers with diversified services throughout the pharmaceutical research and development.

More
NEWS

News

  • Company News
  • |
  • Pharm News
2020-11-10

The EG-017Ⅱ Phase II Program Seminar and Launching Meeting was successfully held

Recently, the EG-017 Phase II clinical trial program seminar and kick-off meeting jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Ningbo Xijian Pharmaceutical Technology Co., Ltd. was successfully held in the form of offline main venue (Beijing)+online video conference.

2020-10-21

Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection was successfully held

Recently, the Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection (hereinafter referred to as "rhEPO-Fc fusion protein") jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Shandong Danhong Pharmaceutical (a wholly-owned subsidiary of Buchang Pharmaceutical) was successfully held in the form of offline main venue (Beijing)+online video conference.

2020-09-29

Drug R&D and Transformation CXO Whole Industry Chain Innovation The service forum is a complete success, and the new leadership opens a new era of CXO in an all-round way!

On September 27th, the "Sub-Forum 5 of the Second Zhengzhou International Biomedical Development Summit Forum-CXO Innovation Service Forum of Pharmaceutical R&D and Transformation Industry Chain", jointly sponsored by the Pharmaceutical Chamber of Commerce of All-China Federation of Industry and Commerce, R&D and Transformation Service Professional Committee of China Food and Drug Enterprise Quality and Safety Promotion Association, and Shenzhen Shenlanhai, a new leader in Beijing, was a complete success! Experts, scholars and enterprise representatives gathered together to discuss the development direction of CXO's innovative service in the whole industrial chain, and help the innovation and development of China's biomedical industry.

More
2020-09-11

第三批集采结果正式出炉!中小型药企路在何方?-浅析中小型药企的生存之道

距离第二批集采已半年有余,疫情挡不住全面深化药品集中采购和使用改革的步伐。8月24日,上海阳光医药采购网发布《关于公布全国药品集中采购中选结果的通知》,第三批集采中选结果正式出炉。

2020-08-18

中国CAR-T细胞治疗研发趋势

自2017年底《细胞治疗产品研究与评价技术指导原则(试行)》出台后,国内CAR-T细胞治疗产品面临“重新洗牌”,各产品临床试验需要重新进行注册申报。据Clinicaltrials.gov数据库,截止报告日期(2020年3月5日),国内已正式开展148个临床试验;结合国内临床试验注册数据,共涉及CAR-T细胞治疗产品131个。

2020-08-08

我国的药品专利链接要来了,仿制药企业该如何应对

药品研发具有周期长、投入高、风险大的特点,因此,需要借助相关制度的设计,对药品研发的成果予以充分保护。其中,药品专利补偿制度和药品专利链接制度的建立就是其中重要的一项。

More